1. IntroductionCommunity-acquired urinary tract infections (UTI) are a public health problem worldwide and the second most frequent infections after respiratory infections [1].Importantly, UTI epidemiology has changed due to the emergence of extended spectrum beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) [2,3]. Until the late 1990s, the majority of identified ESBLs were TEM-1/2 or SHV-1 mutants. The producing strains were often associated with nosocomial epidemics, and the prevalence of ESBL producers was higher in Klebsiella pneumoniae than in Escherichia coli isolates [4,5].However, in the late 1980s–early 1990s, new ESBL types were reported in Europe (MEN-1, CTX-M-1, PER-1), Japan (SFO-1, Toho-1), Argentina (CTX-M-2, PER-2) and Mexico (TLA-1) [4,6,7]. Since the 2000s, CTX-M-producing E. coli strains are the main ESBL-E detected in adult and paediatric UTIs, including in community settings. This phenomenon has accelerated in recent years, and CTX-M is now the main ESBL worldwide. The significant increase in ESBL-E prevalence has led to a parallel increase in carbapenem prescriptions in hospital and community settings [3,8,9]. Consequently, recently, Enterobacterales producing beta-lactamases that hydrolyse class A, B and D carbapenems have been identified worldwide [10]. OXA-48-type (class D) carbapenemases were first detected in K. pneumoniae in Turkey in 2001 [11]. Since then, Enterobacterales producing these enzymes have been found worldwide [12,13]. This is a public health issue because these bacteria are often ESBL-producers, and may also exhibit resistance to other antibiotic classes, particularly fluoroquinolones and aminoglycosides [14]. Therefore, the objective of this study was to determine the rate of multidrug-resistant Enterobacterales that produce ESBL, AmpC beta-lactamases, carbapenemases and beta-lactamases, as well as their antibiotic resistance profiles in patients with UTI in Djibouti, Republic of Djibouti. 3. DiscussionOver the last decade, Gram-negative ESBL-E have emerged as serious pathogens in hospitals and in the community worldwide [15]. As the emergence of ESBL-E varies in different regions of the world [16], antibiotic resistance must be precisely monitored to propose empirical treatment policies. The increase of ESBL-E is a heavy burden for the management of community-acquired UTIs because these isolates are often MDR-E, increasing the risk of treatment failure [16,17]. In our study, 68 (48%) Enterobacterales isolates were MDR-E. This is lower than in other studies [18,19,20], where the MDR-E rate ranged from 50% to 68.0% and 74.2%. ESBL production was detected in 65 (46%) MDR-E isolates: 58 (41%) E. coli and 7 (5%) K. pneumoniae isolates. In previous studies, the ESBL producer rate among isolates from patients with UTI (mainly community-acquired) was variable: 79% in Lebanon [21], 17% in Egypt [22], 6.7% in Libya [15,23] and 0–2.4% in Spain [19].Among the different ESBLs, CTX-M enzymes are the most frequently detected in different epidemiological settings. The number of reports on community-acquired CTX-M-producing E. coli strains (disease-causing or colonizers) is on the increase [24]. In this study, the predominant ESBL-encoding genes were blaCTX-M (97% of isolates) and blaTEM (3% of isolates). This is in agreement with other studies showing that the CTX-M type has replaced the TEM and SHV types in Enterobacterales isolates in several countries, both in nosocomial and community settings [25,26]. For instance, the CTX-M type was predominant (71.4%) in isolates from urine in Egypt (urinary and stool samples) [22,27]. The relatively higher frequency of blaCTX-M in community-acquired isolates in our study is consistent with CTX-M ESBLs originating from environmental bacteria, unlike TEM or SHV ESBLs [28]. Among the blaCTX-M genes, blaCTX-M-15 was the most frequent (95.4%) in our study, as previously reported, thus highlighting its global spread by clonally related E. coli strains [15].Carbapenems are considered one of the last-line treatments available to treat infections caused by MDR Gram-negative bacteria. Therefore, the emergence of carbapenemase-producing Enterobacterales represents a major public health problem [29]. The first reported OXA-48-producing Enterobacterales isolate was a K. pneumoniae strain isolated in Turkey in 2001 as the cause of hospital-acquired infections [11]. OXA-48-like enzymes have been found worldwide in Enterobacterales isolates and have been widely reported as the source of several hospital outbreaks. Recently, the blaOXA-48 gene has been detected in community isolates in many countries [29,30]. Here, we identified the first two E. coli isolates co-producing β-lactamases OXA-48 alone or with CTX-M15 in Djibouti. The first Algerian community-acquired UTI caused by a K. pneumoniae isolate that co-produced the β-lactamases OXA-48 and SHV-27 was described in 2017 [31]. In addition, one E. coli isolate produced the CMY-2 enzyme, which is the most common AmpC in E. coli [32]. The low frequency of AmpC in UTI-causing E. coli isolates has been reported also in Algeria [33].This study revealed a relatively high resistance rate to most of the antibiotics tested. Resistance to trimethoprim, sulfamethoxazole/amoxicillin/clavulanic acid and ampicillin was particularly alarming. This is consistent with findings in Cameroun [34] and Uganda [35]. This may be explained by the easy access to these antibiotics and their massive and uncontrolled use in Djibouti. The particularly high resistance rates of our isolates to trimethoprim/sulfamethoxazole (cotrimoxazole) could be explained also by other factors specific to our setting, such as the use of cotrimoxazole for prophylaxis in HIV-infected patients and the use of the sulfadoxine/pyrimethamine combination, which shares enzymatic targets with cotrimoxazole, for routine malaria prophylaxis during pregnancy, as previously suggested by a study carried out in Tunisia [36]. As 73.8% of our isolates were sensitive to temocillin, this antibiotic could be a good alternative for the management of UTIs caused by ESBL-E.In our study, 50.34% of Enterobacterales isolates were resistant to ciprofloxacin and 55.17% to ofloxacin. According to Guessennd et al. [37], three types of genes are involved in the resistance of Enterobacterales to quinolones: the “qnr” genes, the genes encoding N-acetyl transferase and the genes encoding the QepA efflux pump. The association of these genes with β-lactam and aminoglycoside resistance mechanisms can induce resistance to fluoroquinolones (e.g., ciprofloxacin, ofloxacin). Our resistance rates to ciprofloxacin and ofloxacin were higher than those reported in other studies (40% for ciprofloxacin and 9.1% for ofloxacin in Cameroon [34], 26% for ciprofloxacin and 35% for ofloxacin in Gabon [38] and 13.75% for ciprofloxacin and 17.5% for ofloxacin in Egypt [39]. This difference could be explained by the first-line use of fluoroquinolones as probabilistic treatment of community-acquired UTIs in Djibouti [40]. Amikacin (11.27%) was the most active antibiotic among aminoglycosides. Aminoglycoside resistance was similar to that reported in Iran (16.7% and 21.8%) [41] and Morocco (8% and 14%) [42]. The apparently preserved efficacy of aminoglycosides could be explained by their frequent parenteral administration, which limits their use. Imipenem and fosfomycin also have maintained excellent activity and could be adopted as therapeutic alternatives. These results are in agreement with Tunisian [36] and European data [43].Phylogenetic analysis is important to identify new groups of emerging bacteria. Most isolates were in the B2 group (43% of isolates), followed by the A (26%), B1 (15%), D (6%), F (6%) and E (4%) groups. In other studies [36,44,45] also, the B2 subgroup was the most common group, especially among CTX-M15-producing E. coli strains. Several studies have shown that CTX-M-15-producing E. coli are among the most prevalent ESBL-producing Enterobacterales species [46] and that the worldwide dissemination of ESBL-producing E. coli is associated with specific clones that harbour a plasmid carrying the blaCTM-X-15 gene. In some African countries, CTX-M-15-producing E. coli belonging to the phylogenetic groups A and D have been detected in extra-intestinal infections [22,47,48,49,50,51].